ClinicalTrials.gg
RecruitingNCT07467512EXALIVERUpdated Oct 26, 2026

Exercise for an Aging Liver (EXALIVER)

An interventional study of Exercise and Usual Care in MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASH - Metabolic Dysfunction-Associated Steatohepatitis and Liver Fibrosis/NASH, sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER). Recruiting at 1 site in Spain. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 26, 2026Now Recruiting1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Fatty Liver with a site in Spain — 11 open to participants now, 12 under way, 4 of them phase 3. Fatty Liver · Spain.

Planned enrollment
18th of 23
40 · median 165
Started
2026
with 1 other
No phase
12 of 28
1 open now
Primary completion
2027-06
later than 2 of 11 live
Registered
26th of 28
by date
Lead sponsor
1 of 28
Consorcio Centro de Investigación Biomédica en Red (CIBER)

Among the 28 studies in Fatty Liver with a site in Spain, this one is the 18th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2026, is one of 12 with no phase, reaches primary completion later than 2 of the 11 other live ones, and was the 26th registered.

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

11 of the 28 studies in Fatty Liver with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Fatty Liver with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn how physical exercise affects liver health in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or at-risk metabolic dysfunction-associated steatohepatitis (MASH); comparing responses between middle-aged adults (40-60 years old) and older adults (70 years and older) of any sex, as well as between participants with low-risk MASLD and high-risk MASH. The main question it aims to answer is:

Could an exercise program reduce liver fat, inflammation and fibrosis, regardless of age and disease severity?

Researchers will compare 4 different groups:

A) older adults with at risk MASH who will exercise B) middle-aged people with at risk MASH who will exercise C) middle-aged people with low-risk MASLD who will exercise D) middle-aged people with low-risk MASLD who will not exercise, receiving usual care.

Participants in the exercise groups will take part in a supervised 12-week exercise program that includes both strength and aerobic training, completed twice a week.

All participants, including those receiving usual care, will have health asssessments before and after the 12-week period to measure changes in liver health.

03

Conditions studied

  • MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
  • MASH - Metabolic Dysfunction-Associated Steatohepatitis
  • Liver Fibrosis/NASH

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Middle-aged adults (40 to 60 years old) and older adults (aged 70 years or older)
  • People diagnosed with Metabolic Disfunction-Associated Steatotic Liver Disease (MASLD); defined as the presence of hepatic steatosis (≥5% fat content) in conjunction with at least one cardiometabolic risk factor (overweight or obesity, dysglycaemia or Type II diabetes, elevated plasma triglycerides, reduced HDL-cholesterol or high blood preassure) with no other discernable cause.
  • People diagnosed with at-risk Metabolic Disfunction-Associated SteatoHepatitis (MASH) according to the following criteria: I) a positive liver (NAS score ≥ 4 points (with at least one point in each of the components of the score: steatosis, lobular inflammation and ballooning, AND significant (F2) or advanced (F3) fibrosis), or II) a FAST score >0.65.

Exclusion criteria

Exclusion Criteria:

  • Descompensated cirrhosis or end-stage liver disease.
  • Other causes of liver disease, such as alcohol abuse or drug-induced, virus-related, or hereditary disease.
  • History of a major adverse cardiovascular event, kidney, endocrine, or neurological disease, bariatric surgery, /AIDS, known inflammatory and/or rheumatologic disease, cancer, or other medical condition in which exercise is absolute .
  • Recent or planned major surgery, as well as anticancer therapies.
  • Participating in a weight loss, a weight-management program or a supervised exercise program (more than 30 minutes three times per week, or 45 minutes twice a week, moderate/vigorous intensity).
  • Body weight instability. Participants must have maintained the body weight registered at screening visit (tolerance: 5%) for more than 3 months.
  • Regular use of medication or compounds that may affect study outcomes based on research staff criteria.
  • Pregnancy and lactation or planned pregnancy (within the study period).
  • Frequent travel over time zones during the study period.
  • Fear of needles and claustrophobia to magnetic resonance imaging (MRI).
  • Low physical function (ie, ambulation dependency)
  • Being unable to understand and to accept the instructions or the study objectives and protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Older adults with at risk MASH who exercise

    Older adults with Metabolic Dysfunction-Associated SteatoHepatitis aged 70 years or older who will complete the supervised 12-week exercise program.

    Behavioral: Exercise

  • Experimental
    Middle-age adults with at risk MASH who exercise

    Middle-aged adults (40 to 60 years old) with at-risk metabolic dysfunction-associated SteatoHepatitis (MASH) who will complete a supervised 12-week exercise program

    Behavioral: Exercise

  • Experimental
    Middle-age adults with MASLD who exercise

    Middle-aged adults (40 to 60 years old) with metabolic dysfunction-associated steatotic liver disease (MASLD) who will complete a supervised 12-week exercise program. This study arm will not recruit new participants. Instead, participants will be selected from a concluded clinical trial (NCT05897073; Study Arm: Experimental - Supervised Exercise Intervention), in which they completed the same exercise program and the same study outcome assessments of the present trial. These participants will be matched by sex, age and potential confounders to the individuals enrolled in the "Middle-aged adults with at-risk MASH who exercise" arm of the present study.

    Behavioral: Exercise

  • Active comparator
    Middle-age adults with MASLD receiving usual care

    Middle-aged adults (40 to 60 years old) with metabolic dysfunction-associated steatotic liver disease (MASLD) who receive usual care. This study arm will not recruit new participants. Instead, participants will be selected from a concluded clinical trial (NCT05897073, Study Arm: No Intervention: Usual-care control group), in which they received usual care and the same study outcome assessments of the present trial. These participants will be matched by sex, age and potential confounders to the individuals enrolled in the "Middle-aged adults with at-risk MASH who exercise" arm of the present study.

    Behavioral: Usual Care

Interventions

  • BehavioralExercise

    The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program to achieve a minimum of 135 minutes per week.

  • BehavioralUsual Care

    Participants will receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion.

06

What researchers measure

Primary outcomes

  1. Change in hepatic fat content

    Hepatic fat content will be determined by Proton Density Fat Fraction (PDFF) assessed by Magnetic Resonance Imaging (MRI)

    Time frame: Change from baseline to 12 weeks

  2. Change in liver inflammation and fibrosis

    Iron-corrected T1 (cT1) will be determined though MRI to reflect liver tissue water content, correlating with histological features of fibroinflammation (ballooning, fibrosis, and NAS)

    Time frame: Change from baseline to 12 weeks

  3. Change in liver stiffness

    Determined by vibration-controlled Transient Elastography (Fibroscan ®, VCTE). This is an ultrasound-based technique widely used in clinical practice to diagnose and monitor fibrosis progression. Liver stifness measurement increases with liver fibrosis.

    Time frame: Change from baseline to 12 weeks.

Secondary outcomes

  1. Change in Enhanced Liver Fibrosis (ELF) Score

    Fasting blood samples will be used to assess the Enhanced Liver Fibrosis (ELF) serum biomarker. The ELF score reflects the risk of advanced liver fibrosis, with higher values indicating higher risk.

    Time frame: Change from baseline to 12 weeks

  2. Change in Pro-C3 serum levels

    Fasting blood samples will be used to asses Pro-C3 serum levels, a biomarker of liver fibrosis. Higher PRO-C3 levels indicate ongoing fibrotic activity

    Time frame: Change from baseline to 12 weeks

  3. Change in NIS4 serum biomarker of liver fibrosis

    Fasting blood samples will be used to asses NIS4, a blood-based diagnostic tool designed to identify patients with at-risk MASH. It generates a composite score stratifying patients by risk.

    Time frame: Change from baseline to 12 weeks

  4. Change in Metabolomics Advanced Steatohepatitis Fibrosis Score (MASEF)

    Fasting blood samples will be used to asses Metabolomics Advanced Steatohepatitis Fibrosis Score (MASEF) in serum samples. Is a proprietary algorithm that generates a numeric score that reflects the likelihood of a patient having at-risk MASH.

    Time frame: Change from baseline to 12 weeks

  5. Change in visceral adipose tissue

    Visceral adipose tissue will be assessed by Magnetic Resonance Imaging (MRI)

    Time frame: Change from baseline to 12 weeks

  6. Change in pancreatic fat content

    Pancreatic fat content will be assessed by Magnetic Resonance Imaging (MRI)

    Time frame: Change from baseline to 12 weeks

  7. Change in abdominal subcutaneous adipose tissue

    Abdominal subcutaneous adipose tissue will be assessed by Magnetic Resonance Imaging (MRI)

    Time frame: Change from baseline to 12 weeks

  8. Change in abdominal intermuscular fat content

    Abdominal intermuscular fat content will be assessed by Magnetic Resonance Imaging (MRI)

    Time frame: Change from baseline to 12 weeks

  9. Change in abdominal intramuscular fat content

    Abdominal intramuscular fat content will be assessed by Magnetic Resonance Imaging (MRI)

    Time frame: Change from baseline to 12 weeks

  10. Change in abdominal skeletal muscle tissue

    Abdominal skeletal muscle tissue will be assessed by Magnetic Resonance Imaging (MRI)

    Time frame: Change from baseline to 12 weeks

  11. Change in values of fasting glucose

    Fasting blood samples will be used to assess glucose

    Time frame: Change from baseline to 12 weeks

  12. Change in values of HbA1c

    Fasting blood samples will be used to assess HbA1c. Higher fasting HbA1C values indicates poorer glucemic control.

    Time frame: Change from baseline to 12 weeks

  13. Change in values of fasting insulin

    Fasting blood samples will be used to assess insulin

    Time frame: Change from baseline to 12 weeks

  14. Change in levels of mean glucose (Continuous Glucose Monitoring)

    24-hour, diurnal and nocturnal mean glucose over 14 days will be assessed by Continuous Glucose Monitoring during 2 weeks

    Time frame: Change from baseline to 12 weeks.

  15. Change in fasting lipid profile

    Fasting blood samples will be used to assess levels of triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol an total cholesterol.

    Time frame: Change from baseline to 12 weeks

  16. Change in alkaline phosphatase

    Fasting blood samples will be used to assess serum alkaline phosphatase using standard clinical chemistry methods.

    Time frame: Baseline to 12 weeks

  17. Change in alanine aminotransferase (ALT)

    Fasting blood samples will be used to assess serum alanine aminotransferase (ALT) using standard clinical chemistry methods.

    Time frame: Baseline to 12 weeks

  18. Change in gamma-glutamyl transferase (GGT)

    Fasting blood samples will be used to assess serum gamma-glutamyl transferase (GGT) using standard clinical chemistry methods.

    Time frame: Baseline to 12 weeks

  19. Change in total bilirubin

    Fasting blood samples will be used to assess total serum bilirubin using standard clinical chemistry methods.

    Time frame: Baseline to 12 weeks

  20. Change in creatinine

    Fasting blood samples will be used to assess serum creatinine using standard clinical chemistry methods.

    Time frame: Baseline to 12 weeks

  21. Change in estimated glomerular filtration rate (eGFR)

    eGFR will be calculated from serum creatinine using a standard equation (e.g., CKD-EPI 2021), as implemented by the study laboratory.

    Time frame: Baseline to 12 weeks

  22. Change in values of C-reactive protein

    Fasting blood samples will be used to assess levels of C-reactive protein. Higher values indicate inflammation in the body.

    Time frame: Change from baseline to 12 weeks

  23. Change in values of interleukin 6

    Fasting blood samples will be used to assess levels of interleukin 6. Higher basal levels often indicating greater inflammation or metabolic stress.

    Time frame: Change from baseline to 12 weeks]

  24. Change in blood pressure

    Systolic and Diastolic blood pressure will be assessed by blood pressure monitor

    Time frame: Change from baseline to 12 weeks

  25. Change in waist, hip and neck circumference

    Circumference will be assessed by measuring tape following the procedures outlined by the International Society for the Advancement of Kinanthropometry

    Time frame: Change from baseline to 12 weeks.

  26. Change in body weight

    Body weight will be measured by a digital scale

    Time frame: Change from baseline to 12 weeks

  27. Change in moderate-to-vigorous physical activity (MVPA)

    Moderate-to-vigorous physical activity (minutes per day) will be estimated from wrist-worn accelerometry recorded over a 2-week monitoring period.

    Time frame: Baseline to 12 weeks

  28. Change in light physical activity

    Light physical activity (minutes per day) will be estimated from wrist-worn accelerometry recorded over a 2-week monitoring period.

    Time frame: Baseline to 12 weeks

  29. Change in sedentary time

    Sedentary time (minutes per day) will be estimated from wrist-worn accelerometry recorded over a 2-week monitoring period.

    Time frame: Baseline to 12 weeks

  30. Change in total activity counts

    Total activity counts per day will be estimated from wrist-worn accelerometry recorded over a 2-week monitoring period.

    Time frame: Baseline to 12 weeks

  31. Change in Subjective sleep quality

    Subjective sleep quality will be assessed by the Pittsburgh Sleep Quality Index (PSQI). Minimum value is 0 (never) and maximum value is 3 (3 or more times per week). Higher values mean a worse outcome.

    Time frame: Baseline to 12 weeks

  32. Change in total sleep time

    Total sleep time (minutes per night) will be estimated from wrist-worn accelerometry recorded over a 2-week monitoring period.

    Time frame: Baseline to 12 weeks

  33. Change in Cardiorespiratory Fitness

    Cardiorespiratory fitness measured by maximum treadmill test

    Time frame: Change from baseline to 12 weeks

  34. Change in Lower-body muscular performance

    Lower body muscular performance measured by chair stand test.

    Time frame: Change from baseline to 12 weeks

  35. Change in Upper muscular strength

    Upper body muscular strength measured by hand grip strength test.

    Time frame: Change from baseline to 12 weeks

  36. Change in Quality of life

    Quality of life will be assessed by the Rand Short Form 36 (SF-36). This questionnaire provides an score ranged from 0 to 100. Higher values mean better quality of life.

    Time frame: Changes from baseline to 12-weeks

  37. Change EuroQol Visual Analogue Scale (EQ-VAS) score

    The EQ-VAS is a vertical 0-100 scale used in the EuroQol EQ-5D instrument to measure a patient's self-rated, current overall health. It ranges from 0 (worst imaginable health) to 100 (best imaginable health), allowing patients to quantify their perceived health status.

    Time frame: Changes from baseline to 12-weeks

  38. Change in mid-thigh subcutaneous adipose tissue area

    Mid-thigh subcutaneous adipose tissue area will be quantified from segmented magnetic resonance imaging (MRI) slices.

    Time frame: Baseline to 12 weeks

  39. Change in mid-thigh intramuscular fat content

    Mid-thigh intramuscular fat content will be quantified from segmented magnetic resonance imaging (MRI) slices.

    Time frame: Baseline to 12 weeks

  40. Change in mid-thigh intermuscular fat content

    Mid-thigh intermuscular fat content will be quantified from segmented magnetic resonance imaging (MRI) slices.

    Time frame: Baseline to 12 weeks

  41. Change in mid-thigh skeletal muscle cross-sectional area

    Mid-thigh skeletal muscle cross-sectional area will be quantified from segmented magnetic resonance imaging (MRI) slices.

    Time frame: Baseline to 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.

Of 136 non-industry interventional studies with no phase under Fatty Liver, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 15 months is below that.

Counting every sponsor, half of 145 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Mar 12, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Oct 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
1 site added, 1 site removed
Show site
  • Hospital General Universitario Gregorio Marañon · Madrid, Spain
Show 1 removed
  • Hospital General Universitario Gregorio Marañon · Madrid, Spain
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed
    Show site
    • Hospital General Universitario Gregorio Marañon · Madrid, Spain
    Show 1 removed
    • Hospital General Universitario Gregorio Marañon · Madrid, Spain
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07467512
Lead sponsor
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Collaborators
Hospital General Universitario Gregorio Marañon, Universidad de Granada, Universidad Politecnica de Madrid, Universidad Complutense de Madrid, Instituto Mixto Universitario Deporte y Salud
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Mar 1, 2026
Primary completion
Jun 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Jose Serra-Rexach, PhD
Contact
joseantonio.serra@salud.madrid.es
+34915868835

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion